natgillin/translations-raw huggingface dataset:
After reviewing current available data on the development of inhibitors in previously untreated patients, the PRAC decided that these data did not support a conclusion that Kogenate Bayer or Helixate NexGen were associated with an increased risk of developing factor VIII inhibitors compared with other products. 
Pärast olemasolevate andmete ülevaatamist inhibiitorite tekke kohta varem ravimata patsientidel otsustas ravimiohutuse riskihindamiskomitee, et need andmed ei kinnitanud järeldust, mille kohaselt ravimite Kogenate Bayer või Helixate NexGen kasutamine on teiste ravimitega võrreldes seotud VIII hüübimisteguri inhibiitorite tekke suurema riskiga.
This is a known risk for all factor VIII products but the authors of the study concluded that children given so-called second generation fulllength recombinant factor VIII products such as Kogenate Bayer or Helixate NexGen were more likely to develop antibodies than those given a third generation recombinant product. 
See on teadaolev riskitegur kõigi VIII hüübimistegurit sisaldavate ravimite puhul, ent uuringu autorid järeldasid, et lastel, kellele manustati nn teise põlvkonna täispikkuses rekombinantseid VIII hüübimistegurit sisaldavaid ravimeid (nagu Kogenate Bayer või Helixate NexGen), oli suurem tõenäosus antikehade tekkeks võrreldes lastega, kellele manustati kolmanda põlvkonna rekombinantset ravimit.
Kogenate Bayer and Helixate NexGen are known as second generation factor VIII products. 
Kogenate Bayer ja Helixate NexGen on teise põlvkonna VIII hüübimistegurit sisaldavad ravimid.
This was an observational study which examined inhibitor development in previously untreated patients (PUPs) with severe haemophilia A who were given recombinant or plasma-derived factor VIII products. 
Tegemist oli vaatlusuuringuga, milles hinnati inhibiitorite teket varem ravimata raske A-hemofiiliaga patsientidel, kellele manustati rekombinantset või vereplasmast pärinevat
The review by the PRAC was triggered by results from a study (the RODIN/PedNet study1) in previously untreated children with haemophilia A who were given different factor VIII products, as well as preliminary data from the European Haemophilia Safety and Surveillance System (EUHASS). 
Ravimiohutuse riskihindamiskomitee hindamise algatamise põhjuseks olid uuringu (RODIN/PedNet uuring1) tulemused varem ravimata A-hemofiiliaga patsientidel, kellele manustati erinevaid VIII hüübimistegurit sisaldavaid ravimeid, ja Euroopa hemofiilia ohutuse jälgimise süsteemi (EUHASS) esialgsed andmed.
Benefits continue to outweigh risks in previously untreated patients 
Varem ravimata patsientidel on kasulikkus endiselt suurem kui riskid.
An increase in inhibitor formation was not seen with other recombinant or plasma-derived factor VIII products. 
Suuremat inhibiitorite teket ei täheldatud teiste rekombinantset või vereplasmast pärinevat VIII hüübimistegurit sisaldavate ravimite puhul.
• Kogenate Bayer and Helixate NexGen can continue to be prescribed and used as appropriate in the management of haemophilia A. Existing risk minimisation measures are considered adequate and should be continued. 
• Kogenate Bayerit ja Helixate NexGeni võib A-hemofiilia raviks vajaduse korral endiselt määrata ja kasutada.
Factor VIII is lacking in patients with haemophilia A and is given to them to allow their blood to clot normally. 
A-hemofiiliaga patsientidel puudub VIII hüübimistegur, mida manustatakse neile ravimina vere normaalse hüübivuse tagamiseks.
A study in previously untreated patients with haemophilia A, which compared several of these, seemed to show that patients who were given Kogenate Bayer or Helixate NexGen (full-length second generation products) were more likely to develop antibodies than those given another factor VIII (a third generation product). 
Uuringust varem ravimata A-hemofiiliaga patsientidel, milles võrreldi mitut hüübimistegurit, võis järeldada, et patsientidel, kellel kasutati ravimeid Kogenate Bayer või Helixate NexGen (täispikkuses teise põlvkonna VIII hüübimistegurit sisaldavad ravimid), oli suurem tõenäosus VIII hüübimisteguri vastaste antikehade tekkeks võrreldes patsientidega, kellel kasutati teist VIII hüübimistegurit sisaldavat ravimit (kolmanda põlvkonna VIII hüübimistegurit sisaldavad ravimid).
They are used to replace the factor VIII that is lacking in patients with haemophilia A, an inherited bleeding disorder. 
Neid ravimeid kasutatakse A-hemofiiliaga - päriliku veritsushäirega - patsientidel puuduva VIII hüübimisteguri asendamiseks.
The recommendations, issued by the Agency's Pharmacovigilance Risk Assessment Committee (PRAC), resulted from a review of the medicines which did not confirm a higher risk of developing a type of antibody (factor VIII inhibitors) against these medicines when compared with other factor VIII products. 
Euroopa Ravimiameti ravimiohutuse riskihindamiskomitee soovitused tehti ravimite hindamise tulemusel, mille kohaselt ei leidnud kinnitust suurem risk teatud tüüpi antikehade (VIII hüübimisteguri inhibiitorite) tekkeks ravimite Kogenate Bayer ja Helixate NexGen vastu võrreldes teiste VIII hüübimistegurit sisaldavate ravimitega.
Although existing measures to minimise all the risks from using the products were considered adequate for both Kogenate Bayer and Helixate NexGen and should be continued, the PRAC recommended that the product information should be updated to reflect results from the RODIN study. 
Kuigi Kogenate Bayeri ja Helixate NexGeni puhul juba võetud riskivähendamise meetmeid peeti piisavaiks ning nende kasutamist tuleb jätkata,
The withdrawal period is 15 days for cattle and five days for pigs and horses. 
Keeluaeg on 15 päeva veistele ning 5 päeva sigadele ja hobustele.
A second dose may be given after 24 hours if required. 
Vajadusel manustatakse 24 tunni pärast teine annus.
This summary was last updated on 18 August 2011. 
Kokkuvõtte viimane uuendus: 18.08.2011.
In very rare cases anaphylactoid reactions may occur and should be treated symptomatically. 
Väga harvadel juhtudel võib esineda anafülaktilisi reaktsioone ja neid tuleb ravida sümptomaatiliselt.
Emdocam meloxicam 
Emdocam meloksikaam
The medicine should not be used in horses producing milk for human consumption. 
Ravimit ei tohi kasutada hobustel, kelle piima tarvitatakse inimtoiduks.
It is available as a clear yellow solution for injection (20 mg/ml). 
Seda turustatakse selge kollase süstelahusena (20 mg/ml).
The European Commission granted a marketing authorisation valid throughout the European Union, for Emdocam to Emdoka bvba on 18 August 2011. 
Euroopa Komisjon andis Emdocami müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Emdoka bvba 18.08.2011.
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the doctor. 
Juhusliku enesesüstimise korral tuleb pöörduda kohe arsti poole ja näidata ravimi pakendi infolehte või etiketti.
Its purpose is to explain how the assessment done by the Committee for Medicinal Products for Veterinary Use (CVMP) on the basis of the documentation provided, led to the recommendation for authorisation and the conditions of use. 
Selles selgitatakse, kuidas veterinaarravimite komitee hinnangu alusel, mis tugineb esitatud dokumentidele, koostati soovitus anda kasutusluba ja ravimi kasutustingimuste soovitused.
The Committee recommended that Emdocam be given a marketing authorisation. 
Komitee soovitas anda Emdocami müügiloa.
As the prostaglandins trigger inflammation, pain, exudation and fever, meloxicam reduces these clinical signs. 
Et prostaglandiinid põhjustavad põletikku, valu, eksudatsiooni ja palavikku, vähendab meloksikaam neid kliinilisi sümptomeid.
Milk can be taken five days after administration in cattle. 
Piima tohib lüpsta 5 päeva pärast veistele manustamist.
People who are hypersensitive (allergic) to NSAIDs should avoid contact with Emdocam. 
Inimesed, kes on mittesteroidsete põletikuvastaste ravimite suhtes ülitundlikud (allergilised), peavad kokkupuudet Emdocamiga vältima.
No studies in cattle, pigs and horses were required as Emdocam is given by injection and has a similar composition as the reference medicine, Metacam. 
Uuringuid veistel, sigadel ja hobustel ei olnud vaja teha, sest Emdocami manustatakse süstina ja selle koostis on samasugune kui võrdlusravimil Metacam.
Emdocam is a medicine for cattle, pigs and horses that contains the active substance meloxicam. 
Emdocam on ravim veistele, sigadele ja hobustele, mis sisaldab toimeainena meloksikaami.
What is the time to allow before the animal can be slaughtered and the meat used for human consumption (withdrawal period)? 
Kui pikk on aeg, millal looma ei või tappa ega tarvitada tema liha toiduks (keeluaeg)?
Therefore the CVMP's view was that, as for Metacam, Emdocam's benefits are greater than its risks when used for the approved indications. 
Seetõttu oli veterinaarravimite komitee seisukohal, et nagu Metacami puhul, on ka Emdocami kasulikkus heaks kiidetud näidustusteks kasutamisel suurem kui sellega kaasnevad riskid.
What is the time to allow before milk can be taken from the animal for human consumption? 
Kui pikk on aeg, millal loomalt ei või inimesele tarbimiseks lüpsta piima?
Other information about Emdocam: 
Muu teave Emdocami kohta
What is Emdocam? 
Mis on Emdocam?
The benefit-risk balance may be found in the scientific discussion module of this EPAR. 
Ravimi kasulikkuse ja riski tasakaal on esitatud käesoleva Euroopa avaliku hindamisaruande teadusliku arutelu kokkuvõttes.
Why has Emdocam been approved? 
Miks Emdocam heaks kiideti?
What is the risk associated with Emdocam? 
Mis riskid Emdocamiga kaasnevad?
Emdocam contains meloxicam, which belongs to a class of medicines called non-steroidal antiinflammatory drugs (NSAIDs). 
Emdocam sisaldab meloksikaami, mis kuulub mittesteroidsete põletikuvastaste ravimite klassi.
In horses, a transient swelling at the injection site can occur but resolves without intervention. 
Hobustel võib esineda mööduvat süstekoha paistetust, aga see kaob iseenesest.
In cattle and pigs, subcutaneous, intramuscular as well as intravenous administration is well tolerated; only a slight transient swelling at the injection site following subcutaneous administration was observed in less than 10% of the cattle treated in clinical studies. 
Subkutaanse manustamise järgset kerget mööduvat süstekoha paistetust täheldati vähem kui 10%-l kliinilistes uuringutes ravitud veistest.
It can be used with oral re-hydration therapy for diarrhoea in calves of over one week of age and in young, non-lactating cattle. 
Seda kasutatakse kõhulahtisuse raviks koos suukaudse rehüdratsioonraviga üle nädala vanustel vasikatel ja noortel mittelakteerivatel veistel.
Emdocam was considered to be bioequivalent with the reference medicine. 
Emdocam on võrdlusravimiga bioekvivalentne.
It is given as a single injection of 0.4 mg per kg body weight into a muscle. 
Seda manustatakse lihasesse ühesüstina, mis sisaldab 0,4 mg ravimit kehakaalu kilogrammi kohta.
Emdocam is ‘bioequivalent' to the reference medicine which means that it is equivalent to Metacam in the way it is absorbed and used by the body. 
Emdocam on bioekvivalentne võrdlusravimiga, mis tähendab, et Emdocam imendub ja toimib organismis samamoodi nagu Metacam.
What is Emdocam used for? 
Milleks Emdocami kasutatakse?
In cattle it is used together with appropriate antibiotics, to reduce clinical signs of acute respiratory infection (infection of the lungs and airways) and to treat acute mastitis (inflammation of the udder). 
Veistel kasutatakse Emdocami koos sobiva antibiootikumiraviga ägeda respiratoorse infektsiooni (kopsu- ja hingamisteede infektsioon) kliiniliste sümptomite vähendamiseks ja ägeda mastiidi (udarapõletik) ravimiseks.
Meloxicam acts by blocking an enzyme called cyclo-oxygenase which is involved in the production of prostaglandins. 
Meloksikaam blokeerib prostaglandiine tootvat ensüümi tsüklooksügenaasi.
It is used in pigs to reduce the symptoms of lameness and inflammation in non-infectious locomotor disorders (diseases that affect the ability to move) and for the treatment of diseases that occur after farrowing (giving birth) such as puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome), together with appropriate antibiotic therapy. 
Sigadel kasutatakse Emdocami mittenakkuslike lokomotoorsete häirete korral lonkamise ja põletikusümptomite vähendamiseks ning poegimisjärgse sepsise ja tokseemia (mastiidi-metriidi agalaktia sündroom) raviks koos sobiva antibiootikumiraviga.
What benefit has Emdocam shown during the studies? 
Milles seisneb uuringute põhjal Emdocami kasulikkus?
How does Emdocam work? 
Kuidas Emdocam toimib?
Emdocam is used in horses to relieve colic (abdominal pain) and the inflammation and pain in musculo-skeletal disorders. 
Emdocami kasutatakse hobustel koolikute (kõhuvalu) ning luu- ja lihaskonna kahjustustega kaasneva põletiku ning valu leevendamiseks.
Emdocam is given as a single injection of 0.6 mg per kg body weight into the horse's vein. 
Emdocami manustatakse hobustele veeni ühe süstina, mis sisaldab 0,6 mg ravimit kehakaalu kilogrammi kohta.
Consequently, Emdocam's benefit is taken as being the same as that of the reference medicine. 
Seetõttu peetakse Emdocami ja võrdlusravimi kasulikkust võrdseks.
Emdocam is a ‘generic' medicine which means that Emdocam is similar to a ‘reference veterinary medicine' already authorised in the EU (Metacam). 
See tähendab, et Emdocam on sarnane võrdlusravimiga, millel juba on Euroopa Liidus müügiluba (Metacam).
How has Emdocam been studied? 
Kuidas Emdocami uuriti?
Emdocam is given in cattle as a single injection of 0.5 mg per kg body weight under the skin or into a vein. 
Emdocami manustatakse veistele naha alla või veeni ühe süstina, mis sisaldab 0,5 mg ravimit kehakaalu kilogrammi kohta.
The CVMP considered that, in accordance with European Union requirements, Emdocam is bioequivalent to Metacam. 
Veterinaarravimite komitee otsustas, et Emdocami ja Metacami bioekvivalentsus on Euroopa Liidu nõuete kohaselt tõendatud.
It is available as tablets (2.5, 5, 7.5, 10 and 15 mg). 
Seda turustatakse tablettidena (2,5, 5, 7,5, 10 ja 15 mg).
The dose is adjusted depending on how well the patient responds to and tolerates the treatment. 
Annust kohandatakse vastavalt sellele, kuidas patsient ravile reageerib ja ravi talub.
The name of the medicine was changed to Olanzapine Cipla on 16 May 2013. 
Ravimi nimetus muudeti Olanzapine Ciplaks 16. mail 2013.
The full EPAR for Olanzapine Cipla can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Euroopa avaliku hindamisaruande täistekst Olanzapine Cipla kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Schizophrenia is a mental illness that has a number of symptoms including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (mistaken beliefs). 
Skisofreenia on vaimuhaigus, millel on mitmesugused sümptomid, sealhulgas mõtlemis- ja kõnehäired, hallutsinatsioonid (ebareaalsete asjade nägemine või kuulmine), kahtlustamine ja luulud.
The European Commission granted a marketing authorisation valid throughout the EU for Olanzapine Neopharma on 14 November 2007. 
Euroopa Komisjon andis Olanzapine Neopharma müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 14. novembril 2007.
The recommended starting dose of Olanzapine Cipla depends on the disease being treated: 10 mg per day is used in schizophrenia and in the prevention of manic episodes, and 15 mg per day in the treatment of manic episodes, unless it is used with other medicines, in which case the starting dose can be 10 mg per day. 
Olanzapine Cipla soovituslik algannus sõltub ravitavast haigusest: skisofreenia korral ja maaniaepisoodide ennetamiseks kasutatakse annust 10 mg ööpäevas ning maaniaepisoodide raviks 15 mg ööpäevas, välja arvatud kasutamisel koos teiste ravimitega, mil algannus võib olla 10 mg ööpäevas.
Previously known as Olanzapine Neopharma. 
Varasem nimetus Olanzapine Neopharma.
It is thought that olanzapine's beneficial effect is due to it blocking receptors for the neurotransmitters 5-hydroxytryptamine (also called serotonin) and dopamine. 
Arvatakse, et olansapiini kasulik toime seisneb neurotransmitterite 5-hüdroksütrüptamiini (serotoniini) ja dopamiini retseptorite blokeerimises.
Since these neurotransmitters are involved in schizophrenia and bipolar disorder, olanzapine helps to normalise the activity of the brain, reducing the symptoms of these diseases. 
Et need neurotransmitterid on seotud skisofreenia ja bipolaarse meeleoluhäirega, aitab olansapiin ajutalitlust normaliseerida ja nende haiguste sümptomeid leevendada.
It can also be used to prevent the recurrence of these episodes (when symptoms come back) in adults with bipolar disorder (a mental illness causing alternating periods of high mood and depression) who have responded to an initial course of treatment. 
Seda tohib kasutada ka episoodide kordumise (sümptomite taastekkimise) ennetamiseks bipolaarse meeleoluhäirega (vaimuhaigus, mille puhul vahelduvad meeleolu liigne tõus ja langus) patsientidel, kellel tekkis esialgne ravivastus.
For more information about treatment with Olanzapine Cipla, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Kui vajate Olanzapine Ciplaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Olanzapine Cipla. 
Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
Because Olanzapine Cipla is a generic medicine and is bioequivalent to the reference medicine, its benefit and risk are taken as being the same as the reference medicine's. 
Et Olanzapine Cipla on geneeriline ravim ja võrdlusravimiga bioekvivalentne, peetakse selle kasulikkust ja riske samadeks mis võrdlusravimil.
This is a summary of the European public assessment report (EPAR) for Olanzapine Cipla. 
See on ravimi Olanzapine Cipla Euroopa avaliku hindamisaruande kokkuvõte.
Olanzapine Cipla is a ‘generic medicine'. 
Olanzapine Cipla on geneeriline ravim.
The Committee recommended that Olanzapine Cipla be given marketing authorisation. 
Komitee soovitas anda Olanzapine Cipla müügiloa.
The CHMP concluded that, in accordance with EU requirements, Olanzapine Cipla has been shown to have comparable quality and to be bioequivalent to Zyprexa. 
Inimravimite komitee järeldas, et vastavalt Euroopa Liidu nõuetele on tõendatud Olanzapine Cipla võrdväärne kvaliteet ja bioekvivalentsus ravimiga Zyprexa.
Its exact mechanism of action is unknown, but it attaches to several receptors on the surface of nerve cells in the brain. 
Olanzapine Cipla täpne toimemehhanism ei ole teada, kuid ravim seondub aju närvirakkude pinnal oleva mitme retseptoriga.
Olanzapine Cipla is also effective in maintaining improvement in patients who have responded to an initial course of treatment. 
Olanzapine Ciplat saab kasutada ka esialgse ravivastusega patsientide paranemistulemuse efektiivseks säilitamiseks.
This means that Olanzapine Cipla is similar to a ‘reference medicine' already authorised in the European Union (EU) called Zyprexa. 
See tähendab, et Olanzapine Cipla on sarnane võrdlusravimiga Zyprexa, millel juba on Euroopa Liidus müügiluba.
Therefore, the CHMP's view was that, as for Zyprexa, the benefit outweighs the identified risk. 
Seetõttu on inimravimite komitee arvamusel, et nagu ka Zyprexa korral, ületab Olanzapine Cipla kasulikkus sellega kaasnevad riskid.
Olanzapine Cipla is used to treat adults with schizophrenia. 
Olanzapine Ciplat kasutatakse täiskasvanud patsientidel skisofreenia ravimiseks.
Because Olanzapine Cipla is a generic medicine, studies in patients have been limited to tests to demonstrate that it is bioequivalent to the reference medicine, Zyprexa. 
Et Olanzapine Cipla on geneeriline ravim, piirdusid patsiendiuuringud katsetega, milles näidati Olanzapine Cipla bioekvivalentsust võrdlusravimiga Zyprexa.
Olanzapine Cipla is also used to treat moderate to severe manic episodes (extremely high mood) in adults. 
Samuti kasutatakse Olanzapine Ciplat täiskasvanute mõõdukate või raskete maaniaepisoodide (meeleolu äärmuslik tõus) raviks.
What are the benefits and risks of Olanzapine Cipla? 
Milles seisneb Olanzapine Cipla kasulikkus ja mis riskid Olanzapine Ciplaga kaasnevad?
The active substance in Olanzapine Cipla, olanzapine, is an antipsychotic medicine. 
Olanzapine Cipla toimeaine olansapiin on antipsühhootikum (psühhoosivastane ravim).
Olanzapine Cipla is a medicine that contains the active substance olanzapine. 
Olanzapine Cipla on ravim, mis sisaldab toimeainena olansapiini.
Other information about Olanzapine Cipla 
Muu teave Olanzapine Cipla kohta
What is Olanzapine Cipla? 
Mis on Olanzapine Cipla?
Why has Olanzapine Cipla been approved? 
Miks Olanzapine Cipla heaks kiideti?
Olanzapine Cipla 1 
Olanzapine Cipla olansapiin
How is Olanzapine Cipla used? 
Kuidas Olanzapine Ciplat kasutatakse?
How has Olanzapine Cipla been studied? 
Kuidas Olanzapine Ciplat uuriti?
How does Olanzapine Cipla work? 
Kuidas Olanzapine Cipla toimib?
What is Olanzapine Cipla used for? 
Milleks Olanzapine Ciplat kasutatakse?
Summary of product characteristics, labelling and package leaflet 
Ravimi omaduste, kokkuvöte, pakendi märgistus ja infoleht
Both studies were extended for one additional year and confirmed the benefits of Ongentys when used long-term. 
Mõlemat uuringut pikendati veel ühe aasta võrra ning need kinnitasid Ongentyse kasulikkust pikaajalisel kasutamisel.
What measures are being taken to ensure the safe and effective use of Ongentys? 
Mis meetmed võetakse, et tagada Ongentyse ohutu ja efektiivne kasutamine?
The full EPAR for Ongentys can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Euroopa avaliku hindamisaruande täistekst Ongentys'e kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Among these, dyskinesia (difficulty controlling movement) may affect around 2 in 10 people. 
Neist düskineesia (tahtmatud liigutused) võib tekkida ligikaudu 2 inimesel 10st.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Ongentys's benefits are greater than its risks and recommended that it be approved for use in the EU. 
Inimravimite komitee otsustas, et Ongentyse kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas ravimi kasutamise Euroopa Liidus heaks kiita.
Ongentys opicapone 
Ongentys opikapoon
In both studies, patients had on average off periods of about 6 to 7 hours at the start of the study. 
Mõlemas uuringus oli patsientide off-perioodide keskmine kestus uuringu algul ligikaudu 6-7 tundi.
Other information about Ongentys 
Muu teave Ongentyse kohta
The benefits of Ongentys in Parkinson's disease were investigated in two main studies. 
Ongentyse kasulikkust Parkinsoni tõve ravis uuriti kahes põhiuuringus.
Ongentys is available as capsules (25 mg and 50 mg) to be taken by mouth. 
Ongentyst turustatakse suukaudsete kapslitena (25 mg ja 50 mg).
The recommended dose is 50 mg, taken once a day at bedtime, at least one hour before or after levodopa combination medicines. 
Soovitatav annus on 50 mg, mida võetakse üks kord ööpäevas enne magamaminekut, vähemalt üks tund enne või pärast levodopat sisaldava ravimikombinatsiooni võtmist.
Fluctuations happen when the effects of the medication wear off and symptoms re-emerge before the next dose is due. 
Vaheldumine tekib siis, kui ravimi toime nõrgeneb ja sümptomid tekivad uuesti enne järgmise annuse manustamise aega.
Ongentys is used when these fluctuations cannot be treated with the standard levodopa-containing combinations alone. 
Ongentyst kasutatakse juhul, kui sellist vaheldumist ei saa ravida ainult levodopat sisaldava standardravimikombinatsiooniga.